Patients receiving DTG experienced relatively few adverse effects during trials. Consistent through each of the naïve trials in patients taking DTG was a rise in serum creatinine, reflective of the inhibition of renal tubular creatinine secretion by OCT2. Other commonly reported effects included diarrhea, headache, nausea, and upper respiratory tract infections. Discontinuation rates were similar between DTG and comparator antiretrovirals. No deaths related to study drug occurred in any trial.